Radioimmunotherapy for non-Hodgkin’s lymphoma

摘要: Radioimmunotherapy (RIT) treatment for lymphoma is a novel targeted therapeutic approach. Several years of development radioimmunotherapeutic compounds came to fruition in February 2002 when the US Food and Drug Administration (FDA) approved yttrium 90 ((90)Y)-ibritumomab tiuxetan ((90)Y-IT) relapsed or refractory, low-grade, transformed B-cell lymphoma. (90)Y-IT uses monoclonal anti-CD20 antibody deliver beta-emitting (90)Y malignant B cells. Clinical trials have demonstrated its efficacy, which largely independent intrinsic activity antibody. A similar radiotherapeutic compound, iodine 131 ((131)I)-tositumomab ((131)I-T), also under consideration approval. The advantages increased efficacy compared native are gained at expense myelotoxicity, dose-limiting but reversible. Other radioimmunoconjugates (RIC), including products Hodgkin's lymphoma, earlier stages development. Studies exploring expanded applications RIT way. has been shown be an effective clinically relevant complementary approach patients with